ArticleScientific reports2014

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Yong Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.